Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study

Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study

ObjectiveThis study analyzes the occurrence and characteristics of adverse drug reactions (ADRs) of dupilumab in children in a real-world setting. It aims to enhance clinical practice and minimize medication safety risks in pediatric patients.MethodsThis prospective study included children receiving...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yanhua Chen, Jiang Ni, Ming Li, Yuan Hong, Kouzhu Zhu, Rong Hong, Li Deng, Zhijie Li, Jie Pu, Ting Yang, Yan Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pediatrics
Subjects:	children dupilumab real world safety adverse drug reactions
Online Access:	https://www.frontiersin.org/articles/10.3389/fped.2024.1524962/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries
by: Amani Alfalasi, et al.
Published: (2025-12-01)

Dupilumab-induced serum sickness-like reaction in a pediatric patient
by: S. Minhaj Rahman, BA, et al.
Published: (2025-02-01)

Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)
by: Marjolein de Bruin-Weller, et al.
Published: (2022-07-01)

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
by: Shaun J. Kilty, et al.
Published: (2022-04-01)

Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma
by: Kenji Mizumura, et al.
Published: (2025-01-01)

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01)

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study
by: Mohammed Hasosah, et al.
Published: (2025-02-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Tumors in the setting of dupilumab use: A review of the literature
by: Shumeng Guo, et al.
Published: (2025-01-01)

Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis
by: Daiki Nakashima, MD, et al.
Published: (2025-05-01)

The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
by: Zhang L, et al.
Published: (2025-01-01)

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
by: Seiichiro Kamimura, et al.
Published: (2025-03-01)

High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study
by: Julia Wicherski, et al.
Published: (2025-02-01)

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
by: Lauletta G, et al.
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Case report: Dupilumab-induced linear psoriasis: a rare presentation
by: Wen Sun, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency
by: Sophia Trombello, et al.
Published: (2025-01-01)

The growth diversity of preterm infants at 0–36 months corrected age in China: a real-world observational study
by: Xia Wang, et al.
Published: (2025-01-01)

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis
by: C. Grote, et al.
Published: (2025-12-01)

Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
by: Nicola Lutzu, et al.
Published: (2025-01-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission
by: Mona Al-Ahmad, MD, FRCPC, et al.
Published: (2025-02-01)

Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study
by: Wu Liming, et al.
Published: (2025-12-01)

Real-world evaluation of select adverse drug reactions and healthcare utilization associated with parenteral Ibuprofen and ketorolac in adult and pediatric patients
by: Mosadoluwa Afolabi, et al.
Published: (2025-01-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study
by: Hyun Ji Lee, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Case report: Atopic dermatitis-like skin manifestations in hypohidrotic ectodermal dysplasia caused by a novel splice site mutation of the EDA gene successfully treated with dupilumab
by: Eri Uchiyama, et al.
Published: (2025-01-01)

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
by: Laura Moliner, MD, et al.
Published: (2025-01-01)

Pharmacometabolomics Enables Real-World Drug Metabolism Sciences
by: Fleur B. Nijdam, et al.
Published: (2025-01-01)

Efficacy of 2 L versus 3 L polyethylene glycol in bowel preparation: a real-world study
by: LI Jiaojun, et al.
Published: (2025-02-01)

Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
by: Eleonora Celletti, et al.
Published: (2025-01-01)

Case Report: Severe ophiasis-pattern alopecia areata with concomitant atopic dermatitis in a 5-year-old boy successfully treated with dupilumab
by: Zhendong Wei, et al.
Published: (2025-02-01)

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data
by: Bogdana Patachi, et al.
Published: (2025-01-01)

Real-world study of phakic refractive lens for correction of high myopia
by: An-Peng Pan, et al.
Published: (2025-02-01)

Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis
by: Jiayuan Qin, et al.
Published: (2025-01-01)

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
by: Amy Perrin Ross, et al.
Published: (2025-01-01)

Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients
by: Meng-Ting Cai, et al.
Published: (2025-01-01)